Gamco Investors INC. ET AL Has $3.13 Million Stake in Surmodics, Inc. (SRDX)
Gamco Investors INC. ET AL decreased its holdings in shares of Surmodics, Inc. (NASDAQ:SRDX) by 4.4% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 100,948 shares of the company’s stock after selling 4,700 shares during the quarter. Gamco Investors INC. ET AL owned about 0.77% of Surmodics worth $3,129,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. Principal Financial Group Inc. boosted its holdings in shares of Surmodics by 4.0% during the first quarter. Principal Financial Group Inc. now owns 102,916 shares of the company’s stock worth $2,475,000 after purchasing an additional 3,978 shares during the last quarter. Texas Permanent School Fund boosted its holdings in shares of Surmodics by 0.9% during the second quarter. Texas Permanent School Fund now owns 9,693 shares of the company’s stock worth $273,000 after purchasing an additional 88 shares during the last quarter. Morgan Stanley boosted its holdings in shares of Surmodics by 8.7% during the first quarter. Morgan Stanley now owns 89,123 shares of the company’s stock worth $2,143,000 after purchasing an additional 7,167 shares during the last quarter. Marshall Wace North America L.P. acquired a new stake in shares of Surmodics during the second quarter worth $751,000. Finally, Trigran Investments Inc. boosted its holdings in shares of Surmodics by 17.6% during the second quarter. Trigran Investments Inc. now owns 1,258,613 shares of the company’s stock worth $35,430,000 after purchasing an additional 188,114 shares during the last quarter. Institutional investors and hedge funds own 84.83% of the company’s stock.
Several research firms have recently issued reports on SRDX. ValuEngine upgraded Surmodics from a “sell” rating to a “hold” rating in a report on Friday, September 1st. BidaskClub upgraded Surmodics from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Surmodics presently has a consensus rating of “Hold” and an average target price of $40.00.
TRADEMARK VIOLATION WARNING: This piece was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/gamco-investors-inc-et-al-has-3-13-million-stake-in-surmodics-inc-srdx/1699946.html.
In related news, VP Joseph J. Stich sold 1,000 shares of Surmodics stock in a transaction on Monday, September 11th. The stock was sold at an average price of $27.28, for a total value of $27,280.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 6.40% of the stock is currently owned by company insiders.
Surmodics, Inc. (NASDAQ SRDX) opened at $30.00 on Monday. Surmodics, Inc. has a fifty-two week low of $21.90 and a fifty-two week high of $32.80. The firm has a market capitalization of $398.01, a price-to-earnings ratio of 58.82 and a beta of 0.78.
Surmodics (NASDAQ:SRDX) last issued its earnings results on Wednesday, November 8th. The company reported $0.18 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.19. Surmodics had a return on equity of 1.45% and a net margin of 1.99%. The firm had revenue of $20.06 million for the quarter, compared to analysts’ expectations of $16.98 million. research analysts expect that Surmodics, Inc. will post -0.28 earnings per share for the current fiscal year.
Surmodics Company Profile
Surmodics, Inc is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device.
Want to see what other hedge funds are holding SRDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Surmodics, Inc. (NASDAQ:SRDX).
Receive News & Ratings for Surmodics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.